Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St futures slip as chip stocks drag; Netflix tumbles
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Goldman sees central bank demand providing a floor for gold prices
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
June 2, 2025 11:14 AM EDTLeerink Partners analyst Faisal Khurshid reiterated a Market Perform rating and $16.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Bottom Line: This morning NRIX announced that partner SAN FP (OP, Risinger) exercised their option to license NRIX's STAT6 program, including development candidate NX-3911. We believe NRIX's STAT6 program has been seen as an interesting... More
